Ovarian masses, a common finding among pre- and post-menopausal women, can be benign or malignant. Ovarian cancer is the leading cause of death from gynecologic malignancy among women living in industrialized countries. According to the current guidelines, measurement of CA125 tumor marker remains the gold standard in the management of ovarian cancer. Recently, HE4 has been proposed as emerging biomarker in the differential diagnosis of adnexal masses and in the early diagnosis of ovarian cancer. Discrimination of benign and malignant ovarian tumors is very important for correct patient referral to institutions specializing in care and management of ovarian cancer. Tumor markers CA125 and HE4 are currently incorporated into the Risk of Ovarian Malignancy Algorithm” (ROMA) with menopausal status for discerning malignant from benign pelvic masses. The availability of a good biomarker such as HE4, closely associated with the differential and early diagnosis of ovarian cancer, could reduce medical costs related to more expensive diagnostic procedures. Finally, it is important to note that HE4 identifies platinum non-responders thus enabling a switch to second line chemotherapy and improved survival.

HE4 in the differential diagnosis of ovarian masses / Teresa, Granato; Porpora, Maria Grazia; Flavia, Longo; Angeloni, Antonio; Manganaro, Lucia; Anastasi, Emanuela. - In: CLINICA CHIMICA ACTA. - ISSN 0009-8981. - STAMPA. - 446:(2015), pp. 147-155. [10.1016/j.cca.2015.03.047]

HE4 in the differential diagnosis of ovarian masses

PORPORA, Maria Grazia;ANGELONI, Antonio;MANGANARO, Lucia;ANASTASI, Emanuela
2015

Abstract

Ovarian masses, a common finding among pre- and post-menopausal women, can be benign or malignant. Ovarian cancer is the leading cause of death from gynecologic malignancy among women living in industrialized countries. According to the current guidelines, measurement of CA125 tumor marker remains the gold standard in the management of ovarian cancer. Recently, HE4 has been proposed as emerging biomarker in the differential diagnosis of adnexal masses and in the early diagnosis of ovarian cancer. Discrimination of benign and malignant ovarian tumors is very important for correct patient referral to institutions specializing in care and management of ovarian cancer. Tumor markers CA125 and HE4 are currently incorporated into the Risk of Ovarian Malignancy Algorithm” (ROMA) with menopausal status for discerning malignant from benign pelvic masses. The availability of a good biomarker such as HE4, closely associated with the differential and early diagnosis of ovarian cancer, could reduce medical costs related to more expensive diagnostic procedures. Finally, it is important to note that HE4 identifies platinum non-responders thus enabling a switch to second line chemotherapy and improved survival.
2015
Ovarian Mass, Epithelial Ovarian Cancer, Tumor Markers, HE4, CA125, ROMA
01 Pubblicazione su rivista::01a Articolo in rivista
HE4 in the differential diagnosis of ovarian masses / Teresa, Granato; Porpora, Maria Grazia; Flavia, Longo; Angeloni, Antonio; Manganaro, Lucia; Anastasi, Emanuela. - In: CLINICA CHIMICA ACTA. - ISSN 0009-8981. - STAMPA. - 446:(2015), pp. 147-155. [10.1016/j.cca.2015.03.047]
File allegati a questo prodotto
File Dimensione Formato  
Granato_HE4-differential-diagnosis_2015.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 375.25 kB
Formato Adobe PDF
375.25 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/780472
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 53
social impact